Long R. Jiao

Long R. Jiao

Auto-generated profile, based on publicly available information

Long R. Jiao

HPB Surgical Unit, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
TGTamara M. H. Gall
Tamara M. H. Gall
JJJimmy Jacob
Jimmy Jacob
Adam E. FramptonAdam E. Frampton
Adam E. Frampton
JKJonathan Krell
Jonathan Krell
CKCharis Kyriakides
Charis Kyriakides
LJLong R. Jiao
Long R. Jiao
Circulating tumor cells (CTCs) disseminate from the primary tumor and travel through the bloodstream and lymphatic system. The detection of and/or increase in the number of CTCs during a patient’s clinical course may be a harbinger of forthcoming overt metastasis. We aimed to examine the impact of 2 different surgical techniques, standard (ST) pancreaticoduodenectomy (PD) and no-touch isolation (NT) PD, on tumor behavior and outcome in patients with pancreatic cancer by using CTCs as biomarkers. In this pilot study, patients were randomized to either ST-PD (n = 6) or NT-PD (n = 6). Intraoperatively, blood samples were taken from the portal vein for measurement of CTCs before and immediately after removal of the tumor. An increase in CTCs was seen in 5 of 6 patients (83%) with ST-PD but no patients with NT-PD (P = .003). In the ST-PD and NT-PD groups, median overall survival was 13.0 and 16.7 months, respectively (P = .33); there was no difference in disease-free survival (P = .42). The use of NT-PD significantly reduced the number of CTCs in the portal vein with no benefit in survival outcomes compared with ST-PD, although more extensive studies are required.

3 August 2020 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
MSMikael H. Sodergren
Mikael H. Sodergren
NMNagina Mangal
Nagina Mangal
HWH. Wasan
H. Wasan
Anguraj SadanandamAnguraj Sadanandam
Anguraj Sadanandam
VBV. P. Balachandran
V. P. Balachandran
NHNagy Habib
Nagy Habib
Advances in surgery, peri-operative care and systemic chemotherapy have not significantly improved the prognosis of pancreatic cancer for several decades. Early clinical trials of immunotherapy have yielded disappointing results proposing other means by which the tumour microenvironment serves to decrease the immune response. Additionally, the emergence of various subtypes of pancreatic cancer has emerged as a factor for treatment responses with immunogenic subtypes carrying a better prognosis. Herein we discuss the reasons for the poor response to checkpoint inhibitors and outline a rationale why combination treatments are likely to be most effective. We review the therapies which could provide optimal synergistic effects to immunotherapy including chemotherapy, agents targeting the stroma, co-stimulatory molecules, vaccinations and methods of immunogenic tumour priming including radiofrequency ablation. Finally, we discuss reasons why peri-operative and in particular neoadjuvant combination treatments are likely to be most effective and should be considered for early clinical trials.

9 January 2013 in Expert Review of Molecular Diagnostics
Verified
Journal Article
Closed access
Adam E. FramptonAdam E. Frampton
Adam E. Frampton
TGTamara Mh Gall
Tamara Mh Gall
Leandro CastellanoLeandro Castellano
Leandro Castellano
JSJustin Stebbing
Justin Stebbing
LJLong R Jiao
Long R Jiao
JKJonathan Krell
Jonathan Krell
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease, despite advances in imaging, surgery and a greater understanding of its molecular biology. Patient outcomes remain poor due to an inability to detect disease early and resistance to anticancer treatments. miRNAs are promised to become ideal cancer biomarkers, as they are tumor and tissue specific and also incredibly stable molecules. So far, large profiling studies of the PDAC miRNome have identified the 'usual suspects' known to be deregulated in solid tumors, such as oncomiR-21, as well as others that could be more robust for differentiating malignant from benign pancreatic disease. However, many of these are yet to be validated clinically. The paper under evaluation provides further evidence for the use of miRNAs as diagnostic biomarkers for PDAC. We have reviewed the use of miRNAs as diagnostic analytes for detecting PDAC in biopsies.

16 May 2014 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
TGT. M. H. Gall
T. M. H. Gall
MBM. Basyouny
M. Basyouny
Adam E. FramptonAdam E. Frampton
Adam E. Frampton
ADA. Darzi
A. Darzi
PZP. Ziprin
P. Ziprin
LJL. R. Jiao
L. R. Jiao

18 August 2021 in Expert Review of Gastroenterology & Hepatology
Verified
Journal Article
Open access
SGShubham Gupta
Shubham Gupta
SKSikandar Khan
Sikandar Khan
MKMichal Kawka
Michal Kawka
RGRohan Gujjuri
Rohan Gujjuri
ICIan Chau
Ian Chau
TGTamara Gall
Tamara Gall
Recurrence is the driving factor for reduced long-term survival in patients following resected hepatocellular carcinoma (HCC). Extensive research efforts have been conducted to understand the molec...

25 October 2022 in Translational Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
MKMichal Kawka
Michal Kawka
SMSau Mak
Sau Mak
SQShengyang Qiu
Shengyang Qiu
TGTamara M. H. Gall
Tamara M. H. Gall
LJLong R. Jiao
Long R. Jiao
Hepatic epithelioid hemangioendothelioma (HEHE)—rare vascular malignancy mimicking cholangiocarcinoma: a case report Michal Kawka, Sau Mak, Shengyang Qiu, Tamara M. H. Gall, Long R. Jiao